Publications by authors named "Kate Byth"

Claim this Profile
C
Correction to "Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor".
Dong-Ming Shen, Kate F Byth, Damien Bertheloot, Simona Braams, Sarah Bradley

J Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor.
Dong-Ming Shen, Kate F Byth, Damien Bertheloot, Simona Braams, Sarah Bradley

J Med Chem· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.
Sandra Torres, Maximilian J Brol, Fernando Magdaleno, Robert Schierwagen, Frank E Uschner, Kate Byth

Front Mol Biosci· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Srividya B Balachander, Steven W Criscione, Kate F Byth, Justin Cidado, Ammar Adam

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
William McCoull, Tony Cheung, Erica Anderson, Peter Barton, Jonathan Burgess, Kate Byth

ACS Chem Biol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative analysis of primary relapse/refractory DLBCL identifies shifts in mutation spectrum.
Danielle M Greenawalt, Winnie S Liang, Sakina Saif, Justin Johnson, Petar Todorov, Kate Byth

Oncotarget· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Nicola J Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley, Kate F Byth

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
William McCoull, Roman D Abrams, Erica Anderson, Kevin Blades, Peter Barton, Kate Byth

J Med Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
William McCoull, Roman D Abrams, Erica Anderson, Kevin Blades, Peter Barton, Kate Byth

J Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists.
Edward J Hennessy, Gurmit Grewal, Kate Byth, Victor M Kamhi, Danyang Li

Bioorg Med Chem Lett· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
Scott A Ezell, Suping Wang, Teeru Bihani, Zhongwu Lai, Shaun E Grosskurth, Kate F Byth

Oncotarget· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.
Edward J Hennessy, Vibha Oza, Ammar Adam, Kate Byth, Lillian Castriotta

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Jeffrey G Varnes, Thomas Gero, Shan Huang, R Bruce Diebold, Claude Ogoe, Kate Byth

Bioorg Med Chem Lett· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Scott A Ezell, Michele Mayo, Teeru Bihani, Suprawee Tepsuporn, Suping Wang, Kate F Byth

Oncotarget· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.
Jiaquan Wu, Francoise Powell, Nicholas A Larsen, Zhongwu Lai, Kate F Byth

ACS Chem Biol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role of TAK1 in regulating mantle cell lymphoma survival.
Daniela Buglio, Sangeetha Palakurthi, Kate Byth, Francisco Vega, Dorin Toader

Blood· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts.
Kate F Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor

Mol Cancer Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Clifford D Jones, David M Andrews, Andrew J Barker, Kevin Blades, Kate F Byth

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.
Malcolm Anderson, David M Andrews, Andy J Barker, Claire A Brassington, Jason Breed, Kate F Byth

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
D Ross Camidge, Mike Pemberton, Jim Growcott, Dereck Amakye, David Wilson, Kate Byth

Cancer Chemother Pharmacol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.
Robert W Wilkinson, Rajesh Odedra, Simon P Heaton, Stephen R Wedge, Nicholas J Keen, Kate F Byth

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor.
Kate F Byth, Catherine Geh, Cheryl L Forder, Sandra E Oakes, Andrew P Thomas

Mol Cancer Ther· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Dongpo Cai, Kate F Byth, Geoffrey I Shapiro

Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors.
Kate F Byth, Janet D Culshaw, Stephen Green, Sandra E Oakes, Andrew P Thomas

Bioorg Med Chem Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
Kate F Byth, Nicola Cooper, Janet D Culshaw, David W Heaton, Sandra E Oakes

Bioorg Med Chem Lett· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis